Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-26T06:22:23.794Z Has data issue: false hasContentIssue false

Part IV - Cannabis, Anxiety, and Mood

Published online by Cambridge University Press:  12 May 2023

Edited by
Deepak Cyril D'Souza ,
David Castle  and
Sir Robin Murray
Deepak Cyril D'Souza
Affiliation:
Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine
David Castle
Affiliation:
University of Tasmania, Australia
Sir Robin Murray
Affiliation:
Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Marijuana and Madness , pp. 107 - 138
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Abrams, D. I., Jay, C. A., Shade, S. B., et al. (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology, 68, 515–521.CrossRefGoogle ScholarPubMed
Agosti, V., Nunes, E., and Levin, F. (2002). Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse, 28, 643–652.CrossRefGoogle ScholarPubMed
Amar, M. B. (2006). Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol, 105, 1–25.CrossRefGoogle Scholar
Aragona, M., Onesti, E., Tomassini, V., et al. (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. Clin Neuropharmacol, 32, 41–47.Google Scholar
Baxter, A. J., Scott, K. M., Vos, T., et al. (2013). Global prevalence of anxiety disorders: A systematic review and meta-regression. Psychol Med, 43, 897–910.CrossRefGoogle ScholarPubMed
Bedi, G., Cooper, Z. D., and Haney, M. (2013). Subjective, cognitive and cardiovascular dose-effect progile of nabilone and dronabinol in marijuana smokers. Addict Biol, 18, 872–881.CrossRefGoogle Scholar
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36, 1219–1226.CrossRefGoogle ScholarPubMed
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.Google Scholar
Black, N., Stockings, E., Campbell, G., et al. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. Lancet Psychiatry, 6, 995–1010.CrossRefGoogle ScholarPubMed
Blanco, C., Hasin, D. S., Wall, M. M., et al. (2016). Cannabis use and risk of psychiatric disorders: Prospective evidence from a US national longitudinal study. JAMA Psychiatry, 73, 388–395.Google Scholar
Bonn-Miller, M. O., Zvolensky, M. J., and Bernstein, A. (2007). Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addict Behav, 32, 49–62.Google Scholar
Borgelt, L., Franson, K., Nussbaum, A., et al. (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33, 195–209.Google Scholar
Bossong, M. G., Van Hell, H. H., Jager, G., et al. (2013). The endocannabinoid system and emotional processing: A pharmacological fMRI study with ∆9-tetrahydrocannabinol. Eur Neuropsychopharmacol, 23, 1687–1697.Google Scholar
Buckner, J. D., Bonn-Miller, M. O., Zvolensky, M. J., et al. (2007). Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav, 32, 2238–2252.Google Scholar
Buckner, J. D., Heimberg, R. G., Matthews, R. A., et al. (2012a). Marijuana-related problems and social anxiety: The role of marijuana behaviors in social situations. Psychol Addict Behav, 26, 151.CrossRefGoogle ScholarPubMed
Buckner, J. D., Heimberg, R. G., and Schmidt, N. B. (2011). Social anxiety and marijuana-related problems: The role of social avoidance. Addict Behav, 36, 129–132.Google Scholar
Buckner, J. D., Heimberg, R. G., Schneier, F. R., et al. (2012b). The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Depend, 124, 128–134.CrossRefGoogle ScholarPubMed
Buckner, J. D., Schmidt, N. B., Bobadilla, L., et al. (2006). Social anxiety and problematic cannabis use: Evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther, 44, 1007–1015.CrossRefGoogle ScholarPubMed
Buckner, J. D., Schmidt, N. B., Lang, A. R., et al. (2008). Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res, 42, 230–239.Google Scholar
Bystritsky, A. (2006). Treatment-resistant anxiety disorders. Mol Psychiatry, 11, 805–814.CrossRefGoogle ScholarPubMed
Campos, A. C., and Guimarães, F. S. (2009). Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry, 33, 1517–1521.CrossRefGoogle ScholarPubMed
Connor, J. P., Stjepanović, D., Le Foll, B., et al. (2021). Cannabis use and cannabis use disorders. Nat Rev Dis Primers, 7, 1–24.Google Scholar
Corroon, J., and Phillips, J. A. (2018). A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res, 3, 152–161.CrossRefGoogle ScholarPubMed
Crippa, J. A., Derenusson, G. N., Ferrari, T. B., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol, 25, 121–130.CrossRefGoogle ScholarPubMed
Crippa, J. A., Guimaraes, F. S., Campos, A. C., et al. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol, 9, 2009.Google Scholar
Crippa, J. A., Zuardi, A. W., Garrido, G. E., et al. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology, 29, 417–426.Google Scholar
Cuttler, C., Spradlin, A., and McLaughlin, R. J. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord, 235, 198–205.Google Scholar
D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar
D’Souza, D. C., and Ranganathan, M. (2015). Medical marijuana: Is the cart before the horse? JAMA, 313, 2431–2432.Google Scholar
De Vries, M., Van Rijckevorsel, D. C., Vissers, K. C., et al. (2017). Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol, 15, 1079–1086.Google Scholar
Degenhardt, L., Charlson, F., Ferrari, A., et al. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry, 5, 987–1012.CrossRefGoogle Scholar
Downey, L. A., King, R., Papafotiou, K., et al. (2013). The effects of cannabis and alcohol on simulated driving: Influences of dose and experience. Accid Anal Prev, 50, 879–886.CrossRefGoogle ScholarPubMed
Fabre, L. F., and McLendon, D. (1981). The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol, 21, 377S–382S.Google Scholar
Feingold, D., Rehm, J., Factor, H., et al. (2018). Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3‐year population‐based longitudinal study. Depress Anxiety, 35, 490–501.CrossRefGoogle ScholarPubMed
Feingold, D., Weiser, M., Rehm, J., et al. (2016). The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacology, 26, 493–505.Google Scholar
Foster, D. W., Buckner, J. D., Schmidt, N. B., et al. (2016). Multisubstance use among treatment-seeking smokers: Synergistic effects of coping motives for cannabis and alcohol use and social anxiety/depressive symptoms. Subst Use Misuse, 51, 165–178.Google Scholar
Frank, B., Serpell, M. G., Hughes, J., et al. (2008). Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ, 336, 199–201.Google Scholar
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., et al. (2009). Distinct effects of Δ9- tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 66, 95–105.CrossRefGoogle ScholarPubMed
Gambino, A., Cabras, M., Panagiotakos, E., et al. (2021). Evaluating the suitability and potential efficiency of cannabis sativa oil for patients with primary burning mouth syndrome: A prospective, open-label, single-arm pilot study. Pain Med, 22, 142–151.CrossRefGoogle ScholarPubMed
Glass, R. M., Uhlenhuth, E. H., Hartel, F. W., et al. (1981). Single‐dose study of nabilone in anxious volunteers. J Clin Pharmacol, 21, 383S–396S.Google Scholar
Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72, 1235–1242.Google Scholar
Health Canada. (2019). Addiction to Cannabis. Available at: www.canada.ca/en/health-canada/services/drugs-medication/cannabis/health-effects/addiction.html. Last accessed 30 October 2022.Google Scholar
Karniol, I. G., Shirakawa, I., Kasinski, N., et al. (1974). Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol, 28, 172–177.Google Scholar
Katzman, M. A., Bleau, P., Blier, P., et al. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14, 1.CrossRefGoogle ScholarPubMed
Kedzior, K. K., and Laeber, L. T. (2014). A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population: A meta-analysis of 31 studies. BMC Psychiatry, 14, 1–22.CrossRefGoogle ScholarPubMed
Kessler, R. C., Chiu, W. T., Demler, O., et al. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62, 617–627.Google Scholar
Korem, N., Zer-Aviv, T. M., Ganon-Elazar, E., et al. (2016). Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clinical Physiol Pharmacol, 27, 193–202.Google Scholar
Leehey, M. A., Liu, Y., Hart, F., et al. (2020). Safety and tolerability of cannabidiol in Parkinson disease: An open label, dose-escalation study. Cannabis Cannabinoid Res, 5, 326–336.Google Scholar
Linares, I. M., Zuardi, A. W., Pereira, L. C., et al. (2019). Cannabidiol presents an inverted U-shaped dose–response curve in a simulated public speaking test. Braz J Psychiatry, 41, 9–14.Google Scholar
Lintzeris, N., Driels, J., Elias, N., et al. (2018). Medicinal cannabis in Australia, 2016: The cannabis as medicine survey (CAMS‐16). Med J Aust, 209, 211–216.Google Scholar
Malik, Z., Bayman, L., Valestin, J., et al. (2017). Dronabinol increases pain threshold in patients with functional chest pain: A pilot double-blind placebo-controlled trial. Dis Esophagus, 30, 1–8.Google Scholar
Mammen, G., Rueda, S., Roerecke, M., et al. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: A systematic review of prospective studies. J Clin Psychiatry, 79, 2248.Google Scholar
Marteau, T. M., and Bekker, H. (1992). The development of a six-item short-form of the state scale of the Spielberger State – Trait Anxiety Inventory (STAI). Br J Clin Psychol, 31, 301–306.CrossRefGoogle ScholarPubMed
Moreno, J. L. L. S., Caldentey, J. G., Cubillo, P. T., et al. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol, 263, 1390–1400.CrossRefGoogle Scholar
Narang, S., Gibson, D., Wasan, A. D., et al. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain, 9, 254–264.CrossRefGoogle ScholarPubMed
National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press, pp. 289–327.Google Scholar
Olfson, M., Marcus, S. C., Tedeschi, M., et al. (2006). Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry, 163, 101–108.Google Scholar
Onaemo, V. N., Fawehinmi, T. O., and D’Arcy, C. (2020). Comorbid cannabis use disorder with major depression and generalized anxiety disorder: A systematic review and meta-analyses of nationally representative epidemiological surveys. J Affect Disord, 281, 467–475.Google Scholar
Peacock, A., Leung, J., Larney, S., et al. (2018). Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 113, 1905–1926.CrossRefGoogle ScholarPubMed
Pertwee, R. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol, 156, 397–411.Google Scholar
Pini, L. A., Guerzoni, S., Cainazzo, M. M., et al. (2012). Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain, 13, 677–684.CrossRefGoogle ScholarPubMed
Rog, D. J., Nurmikko, T. J., Friede, T., et al. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812–819.CrossRefGoogle ScholarPubMed
Shannon, S., Lewis, N., Lee, H., et al. (2019). Cannabidiol in anxiety and sleep: A large case series. Perm J, 23, 18-041.Google Scholar
Skrabek, R. Q., Galimova, L., Ethans, K., et al. (2008). Nabilone for the treatment of pain in fibromyalgia. J Pain, 9, 164–173.Google Scholar
Spinella, T. C., Stewart, S. H., Naugler, J., et al. (2021). Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharmacology, 238, 1965–1977.Google Scholar
Stinson, F. S., Ruan, W. J., Pickering, R., et al. (2006). Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychol Med, 36, 1447.Google Scholar
Thompson, E. R. (2007). Development and validation of an internationally reliable short-form of the Positive and Negative Affect Schedule (PANAS). J Cross-Cult Psychol, 38, 227–242.Google Scholar
Toth, C., Mawani, S., Brady, S., et al. (2012). An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain, 153, 2073–2082.CrossRefGoogle ScholarPubMed
Turna, J., Simpson, W., Patterson, B., et al. (2019). Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. J Psychiatr Res, 111, 134–139.Google Scholar
Twomey, C.D. (2017). Association of cannabis use with the development of elevated anxiety symptoms in the general population: A meta-analysis. J Epidemiol Community Health, 71, 811–816.CrossRefGoogle ScholarPubMed
United Nations (2020). World Drug Report 2020. Vienna: UNODC.Google Scholar
Xue, S., Husain, M. I., Zhao, H., et al. (2020). Cannabis use and prospective long-term association with anxiety: A systematic review and meta-analysis of longitudinal studies. Can J Psychiatry, 66, 126–138.Google Scholar
Zeyl, V., Sawyer, K., and Wightman, R. S. (2020). What do you know about maryjane? A systematic review of the current data on the THC:CBD ratio. Subst Use Misuse, 55, 1223–1227.Google Scholar
Zuardi, A. W., Cosme, R. A., Graeff, F. G., et al. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol, 7(1_suppl), 82–88.Google Scholar
Zuardi, A. W., Hallak, J. E., and Crippa, J. A. (2012). Interaction between cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC): Influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology, 219, 247–249.Google Scholar
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., et al. (1982). Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology, 76, 245–250.Google Scholar

References

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association.Google Scholar
Assari, S., Lankarani, M. M., and Caldwell, C. H. (2018). Does discrimination explain high risk of depression among high-income African American men? Behav Sci, 8, 40.Google Scholar
Bagge, C. L., and Borges, G. (2017). Acute substance use as a warning sign for suicide attempts: A case-crossover examination of the 48 hours prior to a recent suicide attempt. J Clin Psychiatry, 78, 20169.CrossRefGoogle ScholarPubMed
Baggio, S, N’Goran, A. A., Deline, S, et al. (2014). Patterns of cannabis use and prospective associations with health issues among young males. Addiction, 109, 937–945.CrossRefGoogle ScholarPubMed
Bahorik, A. L., Leibowitz, A., Sterling, S. A., et al. (2017). Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord, 213, 168–171.Google Scholar
Bambico, F. R., Katz, N., Debonnel, G., et al. (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci, 27, 11700–11711.Google Scholar
Borges, G., Bagge, C. L., and Orozco, R. (2016). A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord, 195, 63–74.Google Scholar
Bradvik, L. (2018). Suicide risk and mental disorders. Int J Environ Res Public Health, 15, 2028.Google Scholar
Briere, F. N., Fallu, J. S., Descheneaux, A., et al. (2011). Predictors and consequences of simultaneous alcohol and cannabis use in adolescents. Addict Behav, 36, 785–788.Google Scholar
Brook, D. W., Brook, J. S., Zhang, C., et al. (2002). Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry, 59, 1039–1044.Google Scholar
Brook, J. S., Brook, D. W., Arencibia-Mireles, O., et al. (2001). Risk factors for adolescent marijuana use across cultures and across time. J Genet Psychol, 162, 357–374.Google Scholar
Caldeira, K. M., O’Grady, K. E., Vincent, K. B., et al. (2012). Marijuana use trajectories during the post-college transition: Health outcomes in young adulthood. Drug Alcohol Depend, 125, 267–275.Google Scholar
Crane, N. A., Langenecker, S. A., and Mermelstein, R. J. (2015). Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood. Addict Behav, 49, 33–39.Google Scholar
Cuttler, C., Spradlin, A., and McLaughlin, R. J. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord, 235, 198–205.Google Scholar
D’Amico, E. J., Tucker, J. S., Miles, J. N., et al. (2016). Alcohol and marijuana use trajectories in a diverse longitudinal sample of adolescents: Examining use patterns from age 11 to 17 years. Addiction, 111, 1825–1835.Google Scholar
De Gregorio, D., Dean Conway, J., Canul, M. L., et al. (2020). Effects of chronic exposure to low doses of Delta9-tetrahydrocannabinol in adolescence and adulthood on serotonin/norepinephrine neurotransmission and emotional behaviors. Int J Neuropsychopharmacol, 23, 751–761.Google Scholar
Degenhardt, L., Coffey, C., Carlin, J. B., et al. (2010). Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry, 196, 290–295.Google Scholar
Degenhardt, L., Coffey, C., Romaniuk, H., et al. (2013). The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction, 108, 124–133.Google Scholar
Delforterie, M. J., Lynskey, M. T., Huizink, A. C., et al. (2015). The relationship between cannabis involvement and suicidal thoughts and behaviors. Drug Alcohol Depend, 150, 98–104.CrossRefGoogle ScholarPubMed
Epstein, M., Hill, K. G., Nevell, A. M., et al. (2015). Trajectories of marijuana use from adolescence into adulthood: Environmental and individual correlates. Dev Psychol, 51, 1650–1663.Google Scholar
Fergusson, D. M., and Horwood, L. (1997). Early onset cannabis use and psychosocial adjustment in young adults. Addiction, 92, 279–296.Google Scholar
Fergusson, D. M., Horwood, L. J., and Swain‐Campbell, N. (2002). Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction, 97, 1123–1135.Google Scholar
Fleming, C. B., Mason, W. A., Mazza, J. J., et al. (2008). Latent growth modeling of the relationship between depressive symptoms and substance use during adolescence. Psychol Addict Behav, 22, 186–197.Google Scholar
Georgiades, K., and Boyle, M. H. (2007). Adolescent tobacco and cannabis use: Young adult outcomes from the Ontario Child Health Study. J Child Psychol Psychiatry, 48, 724–731.Google Scholar
Gobbi, G., Atkin, T., Zytynski, T., et al. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis. JAMA Psychiatry, 76, 426–434.Google Scholar
Han, B., Compton, W. M., Einstein, E. B., et al. (2021). Associations of suicidality trends with cannabis use as a function of sex and depression status. JAMA Netw Open, 4, e2113025.Google Scholar
Harder, V. S., Stuart, E. A., and Anthony, J. C. (2008). Adolescent cannabis problems and young adult depression: Male–female stratified propensity score analyses. Am J Epidemiol, 168, 592–601.Google Scholar
Jacobus, J., Squeglia, L., Escobar, S., et al. (2017). Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. Psychopharmacology, 234, 3431–3442.Google Scholar
Ketcherside, A., and Filbey, F. M. (2015). Mediating processes between stress and problematic marijuana use. Addict Behav, 45, 113–118.Google Scholar
Kung, H. C., Pearson, J. L., and Liu, X. (2003). Risk factors for male and female suicide decedents ages 15–64 in the United States. Results from the 1993 National Mortality Followback Survey. Soc Psychiatry Psychiatr Epidemiol, 38, 419–426.Google Scholar
Kung, H. C., Pearson, J. L., and Wei, R. (2005). Substance use, firearm availability, depressive symptoms, and mental health service utilization among white and African American suicide decedents aged 15 to 64 years. Ann Epidemiol, 15, 614–621.Google Scholar
Leadbeater, B. J., Ames, M. E., and Linden-Carmichael, A. N. (2019). Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. Addiction, 114, 278–293.Google Scholar
Lev-Ran, S., Roerecke, M., Le Foll, B., et al. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol Med, 44, 797–810.Google Scholar
Mammen, G., Rueda, S., Roerecke, M., et al. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: A systematic review of prospective studies. J Clin Psychiatry, 79, 2248.Google Scholar
Manrique-Garcia, E., Zammit, S., Dalman, C., et al. (2012). Cannabis use and depression: A longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry, 12, 112.Google Scholar
Marmorstein, N. R., and Iacono, W. G. (2011). Explaining associations between cannabis use disorders in adolescence and later major depression: A test of the psychosocial failure model. Addict Behav, 36, 773–776.Google Scholar
Meier, M. H., Hill, M. L., Small, P. J., et al. (2015). Associations of adolescent cannabis use with academic performance and mental health: A longitudinal study of upper middle class youth. Drug Alcohol Depend, 156, 207–212.Google Scholar
Moitra, E., Christopher, P. P., Anderson, B. J., et al. (2015). Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults. Psychol Addict Behav, 29, 627–632.Google Scholar
Moore, T. H., Zammit, S., Lingford-Hughes, A., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319–328.Google Scholar
Orri, M., Seguin, J. R., Castellanos-Ryan, N., et al. (2021). A genetically informed study on the association of cannabis, alcohol, and tobacco smoking with suicide attempt. Mol Psychiatry, 26, 5061–5070.Google Scholar
Otten, R., and Engels, R. C. (2013). Testing bidirectional effects between cannabis use and depressive symptoms: Moderation by the serotonin transporter gene. Addict Biol, 18, 826–835.Google Scholar
van Ours, J. C., Williams, J., Fergusson, D., et al. (2013). Cannabis use and suicidal ideation. J Health Econ, 32, 524–537.Google Scholar
Patton, G. C., Coffey, C., Carlin, J. B., et al. (2002). Cannabis use and mental health in young people: Cohort study. BMJ, 325, 1195–1198.CrossRefGoogle ScholarPubMed
Pistis, M., Perra, S., Pillolla, G., et al. (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry, 56, 86–94.Google Scholar
Price, C., Hemmingsson, T., Lewis, G., et al. (2009). Cannabis and suicide: Longitudinal study. Br J Psychiatry, 195, 492–497.Google Scholar
Rhew, I. C., Fleming, C. B., Vander Stoep, A., et al. (2017). Examination of cumulative effects of early adolescent depression on cannabis and alcohol use disorder in late adolescence in a community-based cohort. Addiction, 112, 1952–1960.Google Scholar
Rubino, T., and Parolaro, D. (2016). The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol Psychiatry, 79, 578–585.CrossRefGoogle ScholarPubMed
Rubino, T., Prini, P., Piscitelli, F., et al. (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis, 73, 60–69.Google Scholar
Rubino, T., Realini, N., Braida, D., et al. (2009). Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus, 19, 763–772.Google Scholar
Schoeler, T., Theobald, D., Pingault, J. B., et al. (2018). Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: Findings from 40 years of follow-up. Psychol Med, 48, 2169–2176.CrossRefGoogle ScholarPubMed
Scholes-Balog, K. E., Hemphill, S. A., Evans-Whipp, T. J., et al. (2016). Developmental trajectories of adolescent cannabis use and their relationship to young adult social and behavioural adjustment: A longitudinal study of Australian youth. Addict Behav, 53, 11–18.Google Scholar
Shalit, N., Shoval, G., Shlosberg, D., et al. (2016). The association between cannabis use and suicidality among men and women: A population-based longitudinal study. J Affect Disord, 205, 216–224.Google Scholar
Silins, E., Horwood, L. J., Patton, G. C., et al. (2014). Young adult sequelae of adolescent cannabis use: An integrative analysis. Lancet Psychiatry, 1, 286–293.Google Scholar
Smolkina, M., Morley, K. I., Rijsdijk, F., et al. (2017). Cannabis and depression: A twin model approach to co-morbidity. Behav Genet, 47, 394–404.Google Scholar
Van Gastel, W. A., Vreeker, A., Schubart, C. D., et al. (2014). Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. Schizophr Res, 157, 266–270.Google Scholar
Wilkinson, A. L., Halpern, C. T., and Herring, A. H. (2016). Directions of the relationship between substance use and depressive symptoms from adolescence to young adulthood. Addict Behav, 60, 64–70.Google Scholar
Windle, M., and Wiesner, M. (2004). Trajectories of marijuana use from adolescence to young adulthood: Predictors and outcomes. Devel Psychopathol, 16, 1007–1027.Google Scholar
Womack, S. R., Shaw, D. S., Weaver, C. M., et al. (2016). Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men. J Stud Alcohol Drugs, 77, 287-297.Google Scholar
Zhang, X., and Wu, L. T. (2014). Suicidal ideation and substance use among adolescents and young adults: A bidirectional relation? Drug Alcohol Depend, 142, 63–73.Google Scholar

References

Abush, H., Ghose, S., Van Enkevort, E. A., et al. (2018). Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging, 276, 53–64.Google Scholar
Agrawal, A., Nurnberger, J. I. J., and Lynskey, M. T. (2011). Cannabis involvement in individuals with bipolar disorder. Psychiatry Res, 185, 459–461.Google Scholar
Albanese, M. J., Clodfelter, R. C. J., and Khantzian, E. J. (2000). Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry, 61, 916–921.CrossRefGoogle ScholarPubMed
Arjmand, S., Behzadi, M., Kohlmeier, K. A., et al. (2019). Bipolar disorder and the endocannabinoid system. Acta Nuropsychiatr, 31, 193–201.Google Scholar
Bally, N., Zullino, D., and Aubry, J.-M. (2014). Cannabis use and first manic episode. J Affect Disord, 165, 103–108.Google Scholar
Beaulieu, S., Saury, S., Sareen, J., et al. (2012). The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry, 24, 38–55.Google Scholar
Berk, M., Post, R., Ratheesh, A., et al. (2017). Staging in bipolar disorder: From theoretical framework to clinical utility. World Psychiatry, 16, 236–244.Google Scholar
Bitter, S. M., Adler, C. M., Eliassen, J. C., et al. (2014). Neurofunctional changes in adolescent cannabis users with and without bipolar disorder. Addiction, 109, 1901–1909.Google Scholar
Brady, K. T., Sonne, S. C., Anton, R., et al. (1995). Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study. J Clin Psychiatry, 56, 118–121.Google Scholar
Braga, R. J., Burdick, K. E., Derosse, P., et al. (2012). Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res, 200, 242–245.Google Scholar
Christensen, R., Kristensen, P. K., Bartels, E. M., et al. (2007). Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet, 370, 1706–1713.Google Scholar
Cuttler, C., Spradlin, A., and McLaughlin, R. J. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord, 235, 198–205.Google Scholar
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 15, 594–608.Google Scholar
D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar
Duffy, A., Horrocks, J., Milin, R., et al. (2012). Adolescent substance use disorder during the early stages of bipolar disorder: A prospective high-risk study. J Affect Disord, 142, 57–64.Google Scholar
Feingold, D., Weiser, M., Rehm, J., et al. (2015). The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord, 172, 211–218.Google Scholar
Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry, 7, 865–874.Google Scholar
Geller, B., Cooper, T. B., Sun, K., et al. (1998). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry, 37, 171–178.Google Scholar
Gibbs, M., Winsper, C., Marwaha, S., et al. (2015). Cannabis use and mania symptoms: A systematic review and meta-analysis. J Affect Disord, 171, 39–47.Google Scholar
González-Pinto, A., Reed, C., Novick, D., et al. (2010). Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry, 43, 263–270.Google Scholar
Gore, F. M., Bloem, P. J., Patton, G. C., et al. (2011). Global burden of disease in young people aged 10–24 years: A systematic analysis. Lancet, 377, 2093–2102.Google Scholar
Grinspoon, L., and Bakalar, J. B. (1998). The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. J Psychoactive Drugs, 30, 171–177.Google Scholar
Gruber, A. J., Pope, H. G. J., and Brown, M. E. (1996). Do patients use marijuana as an antidepressant? Depression, 4, 77–80.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
Hartberg, C. B., Lange, E. H., Lagerberg, T. V., et al. (2018). Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. Eur Neuropsychopharmacol, 28, 37–47.Google Scholar
Healey, C., Peters, S., Kinderman, P., et al. (2009). Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: A qualitative study. J Affect Disord, 113, 118–126.Google Scholar
Henquet, C., van Os, J., Kuepper, R., et al. (2010). Psychosis reactivity to cannabis use in daily life: An experience sampling study. Br J Psychiatry, 196, 447–453.Google Scholar
Hjorthøj, C., Østergaard, M. L. D., Benros, M. E., et al. (2015). Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: A nationwide, prospective, register-based study. Lancet Psychiatry, 2, 801–808.Google Scholar
Hunt, G. E., Malhi, G. S., Cleary, M., et al. (2016a). Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990–2015: Systematic review and meta-analysis. J Affect Disord, 206, 321–330.Google Scholar
Hunt, G. E., Malhi, G. S., Cleary, M., et al. (2016b). Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: Systematic review and meta-analysis. J Affect Disord, 206, 331–349.Google Scholar
Hurd, Y. L., Spriggs, S., Alishayev, J., et al. (2019). Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A couble-blind randomized placebo-controlled trial. Am J Psychiatry, 176, 911–922.Google Scholar
Jordan Walter, T., Pocuca, N., Young, J. W., et al. (2021). The relationship between cannabis use and cognition in people with bipolar disorder: A systematic scoping review. Psychiatry Res, 297, 113695.Google Scholar
Kim, S.-W., Dodd, S., Berk, L., et al. (2015). Impact of cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry Invest, 12, 349–355.Google Scholar
Lagerberg, T. V., Kvitland, L. R., Aminoff, S. R., et al. (2014). Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res, 215, 101–104.Google Scholar
Lagerberg, T. V., Sundet, K., Aminoff, S. R., et al. (2011). Excessive cannabis use is associated with earlier age at onset in bipolar disorder. Eur Arch Psychiatry Clin Neurosci, 261, 397–405.Google Scholar
Lippard, E. T. C., Mazure, C. M., Johnston, J. A. Y., et al. (2017). Brain circuitry associated with the development of substance use in bipolar disorder and preliminary evidence for sexual dimorphism in adolescents. J Neurosci Res, 95, 777–791.Google Scholar
Manrique-Garcia, E., Zammit, S., Dalman, C., et al. (2012). Cannabis use and depression: A longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry, 12, 112.Google Scholar
Marwaha, S., Winsper, C., Bebbington, P., et al. (2018). Cannabis use and hypomania in young people: A prospective analysis. Schizophr Bull, 44, 1267–1274.Google Scholar
McGuire, P., Robson, P., Cubala, W. J., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry, 175, 225–231.Google Scholar
Merikangas, K. R., Jin, R., He, J.-P., et al. (2012). Prevalence and correlates for bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry, 68, 241–251.Google Scholar
Mongeau-Pérusse, V., Brissette, S., Bruneau, J., et al. (2021). Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial. Addiction, 116, 2431–2442.Google Scholar
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., et al. (2020). Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry, 11, 315.Google Scholar
Ostacher, M. J., Perlis, R. H., Nierenberg, A. A., et al. (2010). Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: Prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry, 167, 289–297.Google Scholar
Østergaard, M. L. D., Nordentoft, M., and Hjorthøj, C. (2017). Associations between substance use disorders and suicide or suicide attempts in people with mental illness: A Danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction, 112, 1250–1259.Google Scholar
Pinto, J. V., Kauer-Sant’Anna, M., and Yatham, L. N. (2021). What impact does bipolar disorder staging have on the use of pharmacotherapy? Expert Opin Pharmacother, 22, 1513–1516.Google Scholar
Pinto, J. V., Medeiros, L. S., da Rosa, G. S., et al. (2019). The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. Neurosci Biobehav Rev, 101, 78–84.Google Scholar
Pinto, J. V., Saraf, G., Frysch, C., et al. (2020). Cannabidiol as a treatment for mood disorders: A systematic review. Can J Psychiatry, 65, 213–227.Google Scholar
Post, R. M., Leverich, G. S., Kupka, R. W., et al. (2010). Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry, 71, 864–872.Google Scholar
Ringen, P. A., Vaskinn, A., Sundet, K., et al. (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med, 40, 1337–1347.Google Scholar
Sagar, K. A., Dahlgren, M. K., Racine, M. T., et al. (2016). Joint effects: A pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS ONE, 11(6), e0157060.Google Scholar
Scavone, A., Timmins, V., Collins, J., et al. (2018). Dimensional and categorical correlates of substance use disorders among Canadian adolescents with bipolar disorder. J Can Acad Child Adolesc Psychiatry, 27, 159–166.Google Scholar
Starzer, M. S. K., Nordentoft, M., and Hjorthøj, C. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry, 175, 343–350.Google Scholar
Stone, J. M., Fisher, H. L., Major, B., et al. (2014). Cannabis use and first-episode psychosis: Relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med, 44, 499–506.Google Scholar
Strakowski, S. M., DelBello, M. P., Fleck, D. E., et al. (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry, 64, 57–64.Google Scholar
Sultan, A. A., Kennedy, K. G., Fiksenbaum, L., et al. (2021). Neurostructural correlates of cannabis use in adolescent bipolar disorder. Int J Neuropsychopharmacol, 24, 181–190.Google Scholar
Szkudlarek, H. J., Desai, S. J., Renard, J., et al. (2019). Delta-9-tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors. Neuropsychopharmacology, 44, 817–825.Google Scholar
UNDOC. (2018). World Drug Report 2018. Global Overview of Drug Demand and Supply. Available at: www.unodc.org/wdr2018 (Last accessed 12 November 2022).Google Scholar
Weiss, R. D., Griffin, M. L., Kolodziej, M. E., et al. (2007). A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry, 164, 100–107.Google Scholar
Wright, M., Di Ciano, P., and Brands, B. (2020). Use of cannabidiol for the treatment of anxiety: A short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res, 5, 191–196.Google Scholar
Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 20, 97–170.Google Scholar
Zorrilla, I., Aguado, J., Haro, J. M., et al. (2015). Cannabis and bipolar disorder: Does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiat Scand, 131, 100–110.Google Scholar
Zuardi, A., Crippa, J., Dursun, S., et al. (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol, 24, 135–137.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Cannabis, Anxiety, and Mood
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Cannabis, Anxiety, and Mood
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Cannabis, Anxiety, and Mood
  • Edited by Deepak Cyril D'Souza, Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine, David Castle, University of Tasmania, Australia, Sir Robin Murray, Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
  • Book: Marijuana and Madness
  • Online publication: 12 May 2023
Available formats
×